home >> news
ASTRAZENECA ANNOUNCES CHANGES TO SENIOR EXECS TEAM
Tuesday, 15 January
AstraZeneca today unveiled changes to its executive leadership team. The new, expanded membership of AstraZeneca’s Senior Executive Team, which comes into effect immediately, includes increased representation of the company’s scientific expertise, key products and key markets.
The changes include the creation of:
Three senior research and development roles responsible for discovery and early stage development in small molecules; discovery and early stage development in biologics; and late stage development.
Three roles representing the commercial regions: North America, Europe and International. A role responsible for global portfolio and product strategy, bridging between the R&D and sales organisation.
As a result of the changes, two senior roles – President of Research and Development, held by Martin Mackay, and Executive Vice President, Global Commercial, held by Tony Zook – have been eliminated. Martin Mackay and Tony Zook will leave the company at the end of January.
The full Senior Executive Team is as follows:
Pascal Soriot, Chief Executive Officer and Executive Director
Simon Lowth, Chief Financial Officer and Executive Director
Mene Pangalos, Executive Vice President, Innovative Medicines
Bahija Jallal, Executive Vice President, MedImmune
Briggs Morrison, Executive Vice President, Global Medicines Development
Paul Hudson, Executive Vice President, North America
Ruud Dobber, Executive Vice President, Europe
Mark Mallon, Executive Vice President, International
David Smith, Executive Vice President, Operations & IS
Lynn Tetrault, Executive Vice President, Human Resources & Corporate Affairs
Katarina Ageborg, Chief Compliance Officer
Jeff Pott, General Counsel
The appointment of Executive Vice President, Global Portfolio & Product Strategy will be made at a later date.
Pascal Soriot, Chief Executive Officer, said: “This new senior executive team structure, that draws heavily from the leadership talent within the company, enables us to bring an even sharper management focus to key pipeline assets, key brands and key markets, and helps us further accelerate decision-making.”
Commenting on Martin Mackay and Tony Zook, Pascal Soriot said: “I would like to thank Martin and Tony for their contribution and the exemplary leadership they have shown in their time at AstraZeneca. We wish them well in their future endeavours.”
Details of AstraZeneca’s Senior Executive Team, including biographies, can be found on the company’s web site at: